Omnicell (NASDAQ:OMCL) Reaches New 12-Month High – What’s Next?

Omnicell, Inc. (NASDAQ:OMCL)’s stock price reached a new 52-week high on Tuesday . The company traded as high as $51.30 and last traded at $51.19, with a volume of 386579 shares. The stock had previously closed at $50.74.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Omnicell in a report on Wednesday, October 8th. Zacks Research downgraded Omnicell from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 9th. Benchmark lifted their price target on Omnicell from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Wells Fargo & Company boosted their price target on Omnicell from $43.00 to $52.00 and gave the company an “overweight” rating in a report on Monday, January 5th. Finally, KeyCorp raised shares of Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price objective on the stock in a research note on Wednesday, January 7th. Four investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Omnicell has an average rating of “Hold” and a consensus target price of $47.83.

Omnicell Stock Performance

The company has a current ratio of 1.44, a quick ratio of 1.21 and a debt-to-equity ratio of 0.14. The firm’s fifty day moving average is $42.05 and its 200 day moving average is $34.75. The company has a market cap of $2.28 billion, a PE ratio of 117.95, a price-to-earnings-growth ratio of 5.47 and a beta of 0.77.

Insider Buying and Selling at Omnicell

In related news, EVP Corey J. Manley sold 6,106 shares of the firm’s stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $49.90, for a total value of $304,689.40. Following the transaction, the executive vice president directly owned 91,674 shares of the company’s stock, valued at approximately $4,574,532.60. This trade represents a 6.24% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 2.52% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of OMCL. Raymond James Financial Inc. purchased a new position in shares of Omnicell during the 2nd quarter worth approximately $26,000. First Horizon Corp purchased a new stake in Omnicell during the 3rd quarter worth about $31,000. Farther Finance Advisors LLC increased its stake in shares of Omnicell by 784.8% during the third quarter. Farther Finance Advisors LLC now owns 1,168 shares of the company’s stock worth $36,000 after buying an additional 1,036 shares during the period. GAMMA Investing LLC raised its holdings in shares of Omnicell by 37.1% in the 2nd quarter. GAMMA Investing LLC now owns 1,694 shares of the company’s stock valued at $50,000 after purchasing an additional 458 shares in the last quarter. Finally, LSV Asset Management purchased a new stake in Omnicell during the third quarter worth approximately $97,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.